<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1371">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143307</url>
  </required_header>
  <id_info>
    <org_study_id>EBT-101-002</org_study_id>
    <nct_id>NCT05143307</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101</brief_title>
  <official_title>Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Study Where EBT-101 Was Administered</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Excision BioTherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Excision BioTherapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants who receive EBT-101 in a treatment protocol will be eligible to participate in&#xD;
      this long-term follow-up (LTFU) study (EBT-101-002).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who receive EBT-101 in a treatment protocol will be eligible to participate in&#xD;
      this LTFU study (EBT-101-002). All participants will have follow-up visits every six months&#xD;
      until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually&#xD;
      on the anniversary of EBT-101 administration until study completion at Year 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">April 2037</completion_date>
  <primary_completion_date type="Anticipated">January 2037</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Long term follow up of participants who received EBT-101</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety of EBT-101</measure>
    <time_frame>15 years</time_frame>
    <description>Long-term safety of EBT-101 will be assessed based on incidence and severity of clinically significant adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 15 years</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Long Term Follow Up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received EBT-101 in a previous intervention study will undergo long term follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EBT-101</intervention_name>
    <description>Long term follow up of participants who received EBT-101</description>
    <arm_group_label>Long Term Follow Up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who received the investigational study intervention EBT-101 in a previous&#xD;
             intervention study&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Participants who did not receive EBT-101 in a previous intervention study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Excision BioTherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director at ExcisionBio</last_name>
    <phone>833-214-2241</phone>
    <email>clinicalscience@excisionbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Lead at ExcisionBio</last_name>
    <email>clinicalscience@excisionbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRISPR</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>adeno-associated virus serotype 9 (AAV9)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

